Assessment of Risks and Benefits of Using Antibiotics Resistance Genes in Mesenchymal Stem Cell-Based Ex-Vivo Therapy
- Author:
Narayan BASHYAL
1
;
Young Jun LEE
;
Jin-Hwa JUNG
;
Min Gyeong KIM
;
Kwang-Wook LEE
;
Woo Sup HWANG
;
Sung-Soo KIM
;
Da-Young CHANG
;
Haeyoung SUH-KIM
Author Information
- Publication Type:TECHNICAL REPORT
- From:International Journal of Stem Cells 2023;16(4):438-447
- CountryRepublic of Korea
- Language:English
-
Abstract:
Recently, ex-vivo gene therapy has emerged as a promising approach to enhance the therapeutic potential of mesenchymal stem cells (MSCs) by introducing functional genes in vitro. Here, we explored the need of using selection markers to increase the gene delivery efficiency and evaluated the potential risks associated with their use in the manufacturing process. We used MSCs/CD that carry the cytosine deaminase gene (CD) as a therapeutic gene and a puromycin resistance gene (PuroR) as a selection marker. We evaluated the correlation between the therapeutic efficacy and the purity of therapeutic MSCs/CD by examining their anti-cancer effect on co-cultured U87/GFP cells. To simulate in vivo horizontal transfer of the PuroR gene in vivo, we generated a puromycin-resistant
